4-ANTIBODY AG
4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Its technology platform Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. The company also develops preclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3. 4-Antibody AG was founded in 2002 and is based in Basel, Switzerland.
4-ANTIBODY AG
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2002-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.4-antibody.com
Total Employee:
251+
Status:
Active
Contact:
+41616332260
Total Funding:
25.75 M CHF
Technology used in webpage:
SPF IPv6 Microsoft Azure DNS PHP Microsoft DNS Made Easy DNS DNS Made Easy Tiggee
Similar Organizations
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Interline Therapeutics
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
Current Employees Featured
Robert F Burns Chief Executive Officer @ 4-Antibody AG
Chief Executive Officer
Investors List
Grazia Equity
Grazia Equity investment in Series A - 4-Antibody AG
Life Sciences Partners
Life Sciences Partners investment in Series A - 4-Antibody AG
Advent Venture Partners
Advent Venture Partners investment in Series A - 4-Antibody AG
Life Sciences Partners
Life Sciences Partners investment in Seed Round - 4-Antibody AG
Grazia Equity
Grazia Equity investment in Seed Round - 4-Antibody AG
BioMedPartners
BioMedPartners investment in Seed Round - 4-Antibody AG
Mulligan BioCapital
Mulligan BioCapital investment in Seed Round - 4-Antibody AG
Official Site Inspections
http://www.4-antibody.com
- Host name: redirection.dnsmadeeasy.com
- IP address: 96.45.83.110
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "4-Antibody AG"
4-Antibody Company Profile 2024: Valuation, Investors ... - PitchBook
4-Antibody General Information Description. Operator of a biopharmaceutical company intended to generate antibody therapeutics focused on immuno-oncology. The company is a …See details»
4-Antibody AG - Basel, Switzerland - bionity.com
4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform. The Company is making this technology available to pharmaceutical …See details»
4-Antibody AG - VentureRadar
4-Antibody AG is a Swiss biotechnology company concentrating on the development and optimization of human therapeutic antibodies by means of a new patented technology …See details»
4-Antibody AG - Overview, News & Similar companies - ZoomInfo
Who is 4-Antibody AG. 4-Antibody has developed a powerful fully-human antibody drug-discovery and optimization technology platform which it is utilizing to generate a no vel pipeline of …See details»
4-Antibody - Products, Competitors, Financials, Employees, …
4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform. The Company is making this technology available to pharmaceutical …See details»
4-Antibody AG - Funding, Financials, Valuation & Investors
4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Search Crunchbase. ... How much funding has this …See details»
4-Antibody AG - Basel, Schweiz - bionity.com
4-Antibody ist ein biopharmazeutisches Unternehmen mit einer leistungsstarken Technologieplattform für die Entdeckung von Wirkstoffen auf der Basis menschlicher …See details»
4-Antibody AG:Company Profile & Technical Research,Competitor …
4-Antibody AG is a company that provides Antibody, Monoclonal antibody, Biopharmaceutical and more. 4-Antibody AG is headquartered in Switzerland Basel-Stadt. 4-Antibody AG was …See details»
4-Antibody AG - Crunchbase
4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology.See details»
4-Antibody - Company Profile - Tracxn
Mar 10, 2024 4-Antibody - Antibody discovery and optimization platform for drug development. Raised a total funding of $20.6M over 2 rounds from 5 investors. 4-Antibody has 3177 …See details»
4-Antibody - F6S
Similar companies AgomAb Therapeutics Nabla Bio Antibody drugs that are more likely to get approved Infinimmune Infinimmune operates as a biotechnology company. Immunome Native …See details»
4-Antibody AG Overview | SignalHire Company Profile
4-Antibody AG is a private company. The company currently specializes in the Staffing and Recruiting area. ... Organization Website: 4-antibody.com : Phone Number: 781-674-4504: 4 …See details»
4-Antibody - startupticker.ch
Jul 3, 2021 4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform. The Company is making this technology available to …See details»
Ludwig Cancer Research
Jan 29, 2013 4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform which is generating an emerging pipeline of antibody …See details»
Agenus Buys 4-Antibody AG In Potential $50 Million Deal
Jan 13, 2014 Agenus intends to maintain 4-Antibody’s current operations in Basel, Switzerland and Jena, Germany, and to retain the 4-Antibody management team as part of the combined …See details»
Organization and expression of immunoglobulin genes
The organization and processes take place during the development and differentiation of B cells. That is, the controlled gene expression during transcription and translation coupled with the …See details»
4-Antibody AG - Tech Stack, Apps, Patents & Trademarks
4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology.See details»
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 …
1 day ago Portfolio Prioritization. Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting CLDN18.2-positive tumor cells.It conditionally activates T cells through the 4-1BB …See details»
Nonclinical and clinical evaluation of monoclonal antibodies and ...
1 day ago Monoclonal antibodies (mAbs) represent the largest class of therapeutic proteins in clinical use. However, the majority of currently marketed mAbs are used for the treatment of …See details»
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 …
2 days ago I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program. PR Newswire. ROCKVILLE, MD, Jan. 6, 2025.See details»